2015
DOI: 10.1007/s00103-015-2253-z
|View full text |Cite
|
Sign up to set email alerts
|

Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 116 publications
0
14
0
1
Order By: Relevance
“…15 In view of reports of overwhelming sepsis and elevated mortality, 16,17 children with asplenia or splenic dysfunction are also included in these recommendations, although the incidence of IMD in these populations may not be higher than their healthy peers. 11 Although authors of previous studies have shown immunization of complement-deficient patients with polysaccharide capsular group A, C, W, and Y meningococcal vaccines to be effective against invasive disease, 18 the use of 4CMenB in these populations has not previously been studied. Accordingly, in this study, we evaluated the immunogenicity and tolerability of 4CMenB in children with congenital or acquired complement deficiencies and with asplenia or splenic dysfunction and compared this with healthy children in the control group.…”
mentioning
confidence: 99%
“…15 In view of reports of overwhelming sepsis and elevated mortality, 16,17 children with asplenia or splenic dysfunction are also included in these recommendations, although the incidence of IMD in these populations may not be higher than their healthy peers. 11 Although authors of previous studies have shown immunization of complement-deficient patients with polysaccharide capsular group A, C, W, and Y meningococcal vaccines to be effective against invasive disease, 18 the use of 4CMenB in these populations has not previously been studied. Accordingly, in this study, we evaluated the immunogenicity and tolerability of 4CMenB in children with congenital or acquired complement deficiencies and with asplenia or splenic dysfunction and compared this with healthy children in the control group.…”
mentioning
confidence: 99%
“…In contrast to the high proportion of HIV-infected IMD cases of about 60% both in the New York outbreak and in MSM ascertained throughout the USA from 2012–2015 [ 7 ], none of the affected MSM in Germany or France were HIV positive. IMD risk was shown to be increased up to over 23-fold in persons with HIV infection (reviewed in [ 30 , 31 ]), but the high coverage with antiretroviral combination therapy in Germany of ~70% [ 32 ] may explain why no MSM with HIV contracted IMD.…”
Section: Discussionmentioning
confidence: 99%
“…Vaccine effectiveness (VE) was estimated at 80% as a relevant proportion of the recurrent IMD patients may have detected or undetected complement deficiencies [23].…”
Section: Number Needed To Vaccinatementioning
confidence: 99%
“…Since 2009, vaccination of household contacts of an IMD case with either a MenC or a MenACWY vaccine has been recommended depending on the serogroup of the index case [22]. Since 2015, this recommendation has been extended to serogroup B [23].…”
Section: Introductionmentioning
confidence: 99%